N/A
Completed N=900
Providing Financial Incentives to Improve Adherence to Referral Eye Care Visits
Source: ClinicalTrials.gov NCT04328207 ↗Enrolled (actual)
900
Serious AEs
0.0%
Results posted
Jul 2025
Primary outcomePrimary: Percentage of Participants That Adhere to Referral Appointment — 80; 92 Participants
Summary
Glaucoma is a blinding eye disease increasingly common in older adults, particularly in African Americans, and often diagnosed late in the disease course. It is essential to develop novel health care models, utilizing telemedicine, to improve the ability to detect glaucoma at an earlier stage, and to provide a platform to manage this disease in community-based clinics so that further vision loss is prevented. Our goal is to improve the quality and accessibility of glaucoma detection and management among a vulnerable and at-risk segment of our population.
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Percentage of Participants That Adhere to Referral Appointment |
80; 92 | — |
Eligibility Criteria
Inclusion Criteria
- African American or Hispanic ≥40 years
- Non-Hispanic white ≥50 years
- Anyone ≥ 18 years with diabetes
- Anyone ≥ 18 years with a glaucoma associated diagnosis
- Anyone ≥ 18 years with a family history of glaucoma
- All enrollees must be able to speak and understand English
Exclusion Criteria
- None
Data sourced from ClinicalTrials.gov (NCT04328207). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication. Informational only — not medical advice.